Jun 2026 (Q2 FY26) — Aug 5, 2026
Zevra Q2 FY26 — Strong MIPLYFFA Growth and Pipeline Advancement Amidst EMA Reexamination
Read the full callZevra (ZVRA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Zevra earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 39.7 | +53.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 42.3 | +316.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 8.8 | −88.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$10.16 +2.21% · +$0.22
Performance −6.0% 1Y
1Y: $10.81 on 17 Oct 2025 → $10.16. High $14.75 (8 Jul 2026), low $8.1 (18 Dec 2025).
- Previous close
- $9.94
- 52-week range
- $8.1 – $14.75
- One year
- −8.88%
Overview
- Symbol
- ZVRA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Zevra earnings calls (ZVRA)
Financials
What the filings say
Net profit, year on year: −88% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 12 | 20 | 26 | 26 | 34 | 36 | 40 |
| Expenses | 27 | 24 | 23 | 24 | 20 | 23 | 25 | 21 |
| Operating profit | -27 | -15 | -5 | -71 | 4 | 9 | 52 | 17 |
| Operating margin | −739.0% | −128.0% | −26.3% | −274.5% | 15.9% | 27.3% | 144.0% | 42.3% |
| Other income | -6 | -5 | 3 | 148 | -5 | 3 | -7 | -4 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 |
| Profit before tax | -33 | -20 | -2 | 77 | -1 | 13 | 45 | 13 |
| Tax rate | 0.0% | −75.5% | −61.7% | 2.9% | 44.3% | 4.0% | 15.4% | 31.6% |
| Net profit | -33 | -36 | -3 | 75 | -1 | 12 | 38 | 9 |
| EPS ($ per share) | -0.69 | — | -0.06 | 1.24 | -0.01 | — | 0.62 | 0.14 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Reserves | -221 | -246 | -258 | -267 | -354 | -400 | -505 | -422 |
| Total liabilities | 93 | 85 | 78 | 6 | 40 | 110 | 138 | 130 |
| Fixed assets | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Investments | 3 | — | — | 0 | — | — | — | — |
| Total assets | 27 | 11 | 11 | 133 | 115 | 172 | 178 | 285 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -54 | -24 | -2 | 10 | -19 | -34 | -70 | -2 |
| Cash from investing | 33 | 3 | -0 | -16 | -37 | -17 | -22 | 18 |
| Cash from financing | 28 | 5 | 3 | 113 | 8 | 28 | 82 | 12 |
| Net cash flow | 7 | -16 | 1 | 108 | -47 | -22 | -9 | 29 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -1 |
| Free cash flow | -54 | -24 | -2 | 10 | -19 | -34 | -70 | -2 |
Insider filings
28 filings between Dec 31, 2025 and Oct 12, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.52M
13 sales by 6 insiders
92% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Option exercise — converted options into shares
- 1
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| McFarlane Neil F. | — | $1.20M | Oct 12, 2026 |
| Thompson Rahsaan | — | $969.4K | Aug 14, 2026 |
| Watton Corey Michael | — | $138.4K | Aug 10, 2026 |
| Schafer Joshua | — | $126.3K | Feb 3, 2026 |
| Sangiovanni Timothy J. | — | $43.0K | Feb 3, 2026 |
| Quartel Adrian W | — | $40.0K | Jan 30, 2026 |
Latest filings (47)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 12, 2026 | McFarlane Neil F. President and CEO | Sale 10b5-1 plan | 20,000 | $224.9K |
| Oct 10, 2026 | McFarlane Neil F. President and CEO | Option exercise 10b5-1 plan | 50,000 | — |
| Aug 14, 2026 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 plan | 42,666 | $474.8K |
| Aug 10, 2026 | Watton Corey Michael Director | Sale | 12,300 | $138.4K |
| Aug 10, 2026 | Watton Corey Michael Director | Option exercise | 12,300 | $61.1K |
| Jun 22, 2026 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 plan | 34,557 | $438.3K |
| Jun 21, 2026 | Thompson Rahsaan Chief Legal & Compliance | Option exercise 10b5-1 plan | 66,667 | — |
| May 11, 2026 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 plan | 1,794 | $20.3K |
| Mar 24, 2026 | Bode John B Director | Option exercise | 39,200 | $194.8K |
| Mar 24, 2026 | Bode John B Director | Option exercise | 39,200 | $191.7K |
| Feb 9, 2026 | McFarlane Neil F. President and CEO | Sale 10b5-1 plan | 14,625 | $125.2K |
| Feb 7, 2026 | McFarlane Neil F. President and CEO | Option exercise 10b5-1 plan | 37,500 | — |
| Feb 3, 2026 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Sale 10b5-1 plan | 3,000 | $27.5K |
| Feb 3, 2026 | Schafer Joshua CCO | Sale 10b5-1 plan | 10,500 | $96.5K |
| Feb 2, 2026 | McFarlane Neil F. President and CEO | Sale 10b5-1 plan | 91,000 | $853.4K |
| Jan 31, 2026 | McFarlane Neil F. President and CEO | Option exercise 10b5-1 plan | 233,334 | — |
| Jan 31, 2026 | Schafer Joshua CCO | Option exercise 10b5-1 plan | 35,334 | — |
| Jan 31, 2026 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Option exercise 10b5-1 plan | 11,666 | — |
| Jan 30, 2026 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 plan | 4,080 | $36.0K |
| Jan 30, 2026 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Option exercise 10b5-1 plan | 6,333 | — |
| Jan 30, 2026 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Sale 10b5-1 plan | 1,750 | $15.4K |
| Jan 30, 2026 | Thompson Rahsaan Chief Legal & Compliance | Option exercise 10b5-1 plan | 11,333 | — |
| Jan 30, 2026 | Quartel Adrian W Chief Medical Officer | Option exercise 10b5-1 plan | 11,333 | — |
| Jan 30, 2026 | Quartel Adrian W Chief Medical Officer | Sale 10b5-1 plan | 4,533 | $40.0K |
| Jan 30, 2026 | Schafer Joshua CCO | Option exercise 10b5-1 plan | 11,333 | — |
| Jan 30, 2026 | Schafer Joshua CCO | Sale 10b5-1 plan | 3,375 | $29.8K |
| Dec 31, 2025 | Clifton R. LaDuane Insider | Option exercise | 140,667 | $0 |
| Dec 31, 2025 | Clifton R. LaDuane Insider | Tax withheld | 48,513 | $434.7K |
| Oct 10, 2025 | McFarlane Neil F. President and CEO | Option exercise 10b5-1 plan | 50,000 | — |
| Oct 10, 2025 | McFarlane Neil F. President and CEO | Sale 10b5-1 plan | 19,500 | $210.9K |
| Sep 12, 2025 | FAVORITO TAMARA A Director | Purchase | 3,175 | $24.7K |
| Sep 12, 2025 | Shih Alvin Director | Purchase | 20,000 | $157.8K |
| Aug 19, 2025 | Bode John B Director | Purchase | 5,000 | $45.8K |
| Jun 26, 2025 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 plan | 24,000 | $221.0K |
| Jun 21, 2025 | Thompson Rahsaan Chief Legal & Compliance | Option exercise | 66,666 | — |
| Mar 28, 2025 | Watton Corey Michael Director | Purchase | 300 | $2.4K |
| Mar 19, 2025 | Bode John B Director | Purchase | 10,000 | $79.6K |
| Feb 14, 2025 | McFarlane Neil F. President and CEO | Sale 10b5-1 plan | 30,544 | $246.0K |
| Feb 13, 2025 | Schafer Joshua CCO & EVP, Bus. Development | Sale 10b5-1 plan | 10,500 | $82.5K |
| Feb 13, 2025 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Sale 10b5-1 plan | 3,000 | $23.6K |
| Feb 13, 2025 | McFarlane Neil F. President and CEO | Sale 10b5-1 plan | 61,273 | $481.4K |
| Feb 13, 2025 | Clifton R. LaDuane CFO & Treasurer | Sale 10b5-1 plan | 11,000 | $86.5K |
| Jan 31, 2025 | Schafer Joshua CCO & EVP, Bus. Development | Option exercise | 35,333 | — |
| Jan 31, 2025 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Option exercise | 11,666 | — |
| Jan 31, 2025 | McFarlane Neil F. President and CEO | Option exercise | 233,333 | — |
| Jan 31, 2025 | Clifton R. LaDuane CFO & Treasurer | Option exercise | 43,333 | — |
| Oct 11, 2024 | Watton Corey Michael Director | Purchase | 500 | $4.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for ZEVRA THERAPEUTICS, INC.
Free account. Everything above stays public.
Write why you follow ZEVRA THERAPEUTICS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading